Picture of CEL-SCI logo

CVM — CEL-SCI Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Momentum

Relative Strength (%)
1m-28.66%
3m-49.02%
6m-28.83%
1yr-66.2%
Volume Change (%)
10d/3m-12.16%
Price vs... (%)
52w High-85.53%
50d MA-33.91%
200d MA-54.7%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-50.32%
Return on Equity-96.28%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Sep 202230th Sep 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of CEL-SCI EPS forecast chart

Profile Summary

CEL-SCI Corp is a clinical-stage biotechnology company. The Company is focused on activating the immune system to fight cancer and infectious diseases. The Company is engaged in research and developing the treatments for the cancer and other diseases by using the immune system. The Company’s lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal Phase 3 clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The Company using its Ligand Epitope Antigen Presentation System (LEAPS) technology platform is investigating product candidates include CEL-2000 and CEL-4000. CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis. It is also investigating LEAPS COVID-19 conjugates as a potential treatment of coronavirus (COVID-19) in hospitalized and at-high-risk patients at the University of Georgia’s (UGA) Center.

Directors

Last Annual
September 30th, 2021
Last Interim
September 30th, 2021
Incorporated
March 22nd, 1983
Public Since
December 8th, 1983
No. of Shareholders
559
No. of Employees
43
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNYSE MKT
Shares in Issue
43,244,498

CVM Share Price Performance

Latest News for CVM

Upcoming Events for CVM

Q1 2022 CEL-SCI Corp Earnings Release

Q2 2022 CEL-SCI Corp Earnings Release

CEL-SCI Corp Annual Shareholders Meeting

Similar to CVM

Picture of cbdMD logo

cbdMD

us flag iconNYSE MKT

Picture of Ibio logo

Ibio

us flag iconNYSE MKT

FAQ

Or unlock with your email

Or unlock with your email